Tan W C
Division of Respiratory Medicine, National University Hospital, Singapore.
Ann Acad Med Singap. 1991 Jan;20(1):165-71.
The emphasis in the treatment of bronchial asthma has shifted from that of bronchial hyper-responsiveness to that of airway inflammation. Bronchodilators still form the mainstay of treatment for all categories of asthma. However, only anti-allergic drugs and corticosteroids can modify inflammation and long-term usage offers the hope of suppression of the disease and prevention of progressive airway obstruction. The safety of inhaled steroids has enabled specific treatment to be extended to milder asthma. Correct treatment will not succeed without patient compliance and good inhaler technique. The ultimate aim of therapy is the reduction of morbidity and mortality and the prevention of irreversible airway obstruction.
支气管哮喘的治疗重点已从支气管高反应性转移到气道炎症。支气管扩张剂仍然是各类哮喘治疗的主要手段。然而，只有抗过敏药物和皮质类固醇能够改变炎症，长期使用有望抑制疾病并预防进行性气道阻塞。吸入性类固醇的安全性使得特异性治疗能够扩展到轻度哮喘。没有患者的依从性和良好的吸入技术，正确的治疗就不会成功。治疗的最终目标是降低发病率和死亡率，预防不可逆的气道阻塞。
